Bulletin from Annual General Meeting in Boule Diagnostics AB on May 5, 2022
The Annual General Meeting 2022 (the ”AGM”) decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2021. Furthermore, a dividend to shareholders of SEK 0.55 was approved for 2021 and the remaining profit shall be carried forward.
The AGM also decided to discharge the board members and the CEO from liability for 2021.
The AGM approved the nominating committee’s proposal that the board shall consist of five board members.
The AGM decided that the remuneration to the chairman of the board shall amount to SEK 500,000 (470,000 for 2021) and that the remuneration to the other board members shall be SEK 250,000 (235,000 for 2021) each. In addition, it was approved that SEK 120,000 (0 for 2021) will be the total remuneration to a newly established audit committee, to be distributed within itself, as well as an amount of up to SEK 50,000 that the board can use for special initiatives. This primarily refers to work with remuneration issues, such as share-based incentives for company executives. The total remuneration to the board is hence SEK 1,670,000 (SEK 1,880,000 for 2021).
The AGM also decided that the remuneration to the auditor as previous will be on specified current account approved by the board.
The AGM decided that the board until the end of the next Annual General Meeting will consist of the members Karin Dahllöf, Thomas Eklund, Torben Jørgensen, Jon Risfelt and Yvonne Mårtensson through re-election. Yvonne Mårtensson was elected chairwoman of the board.
Öhrlings PriceWaterhouseCoopers AB was re-elected as the company’s auditor, with Lars Kylberg as auditor in charge, until the end of the Annual General Meeting of 2023.
The AGM approved the proposed principles and instructions for the nomination committee.
The AGM approved the board’s presented remuneration report for 2021.
The AGM approved the board’s proposal to be authorized to increase share capital through the issue of new shares, warrants and/or convertibles.
The AGM approved the board’s proposal to be authorized to make decisions on the acquisition and/or transferal of own shares.
The AGM approved the board’s proposal to amend the articles of association.
Complete proposals regarding the AGM’s decisions are available in Swedish on Boule’s websitehttp://www.boule.com.
For more information, please contact: Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Annette Colin, CFO, Boule Diagnostics AB, phone +46 (0)70-319 06 76
About Boule Diagnostics AB (publ) Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com
The information was submitted for publication, through the agency of the contact person set out above, at 19.30 CET on May 5, 2022.